Spots Global Cancer Trial Database for stage iv urethral cancer

Every month we try and update this database with for stage iv urethral cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers	NCT01846520	Healthy Subject Localized Trans... Metastatic Tran... Psychosocial Ef... Recurrent Bladd... Recurrent Cervi... Recurrent Colon... Recurrent Gastr... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Recurrent Trans... Recurrent Ureth... Recurrent Uteri... Regional Transi... Stage II Bladde... Stage II Renal ... Stage II Urethr... Stage IIA Cervi... Stage IIA Colon... Stage IIA Gastr... Stage IIA Ovari... Stage IIA Ovari... Stage IIA Pancr... Stage IIA Recta... Stage IIA Uteri... Stage IIB Cervi... Stage IIB Colon... Stage IIB Gastr... Stage IIB Ovari... Stage IIB Ovari... Stage IIB Pancr... Stage IIB Recta... Stage IIB Uteri... Stage IIC Colon... Stage IIC Ovari... Stage IIC Ovari... Stage IIC Recta... Stage III Bladd... Stage III Pancr... Stage III Renal... Stage III Ureth... Stage IIIA Cerv... Stage IIIA Colo... Stage IIIA Gast... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Uter... Stage IIIB Cerv... Stage IIIB Colo... Stage IIIB Gast... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Uter... Stage IV Bladde... Stage IV Gastri... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Urethr... Stage IVA Cervi... Stage IVA Colon... Stage IVA Recta... Stage IVA Uteri... Stage IVB Cervi... Stage IVB Colon... Stage IVB Recta... Stage IVB Uteri... Ureter Cancer Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIB Lung...	educational int... telephone-based... quality-of-life... questionnaire a...	18 Years -	City of Hope Medical Center
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer	NCT02437370	Metastatic Urot... Recurrent Bladd... Recurrent Uroth... Regional Urothe... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Urethral Urothe...	Pembrolizumab Docetaxel Gemcitabine Hyd...	18 Years -	University of California, Davis
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer	NCT01118039	Bladder Cancer Transitional Ce... Urethral Cancer	sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer	NCT02437370	Metastatic Urot... Recurrent Bladd... Recurrent Uroth... Regional Urothe... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Urethral Urothe...	Pembrolizumab Docetaxel Gemcitabine Hyd...	18 Years -	University of California, Davis
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer	NCT01118039	Bladder Cancer Transitional Ce... Urethral Cancer	sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Afatinib in Advanced Refractory Urothelial Cancer	NCT02122172	Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer	afatinib dimale... laboratory biom...	18 Years -	University of Chicago
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer	NCT02437370	Metastatic Urot... Recurrent Bladd... Recurrent Uroth... Regional Urothe... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Urethral Urothe...	Pembrolizumab Docetaxel Gemcitabine Hyd...	18 Years -	University of California, Davis
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium	NCT01090466	Bladder Cancer Transitional Ce... Urethral Cancer	cisplatin gemcitabine hyd... temsirolimus pharmacological...	16 Years - 120 Years	Cardiff University
Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment	NCT01031875	Bladder Cancer Transitional Ce... Urethral Cancer	pazopanib hydro... fludeoxyglucose...	18 Years -	National Cancer Institute (NCI)
Afatinib in Advanced Refractory Urothelial Cancer	NCT02122172	Distal Urethral... Proximal Urethr... Recurrent Bladd... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Ureter Cancer	afatinib dimale... laboratory biom...	18 Years -	University of Chicago
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer	NCT01118039	Bladder Cancer Transitional Ce... Urethral Cancer	sunitinib malat... immunohistochem... laboratory biom... pharmacological... quality-of-life...	18 Years -	National Cancer Institute (NCI)
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma	NCT00072150	Metastatic Tran... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Transitional Ce... Ureter Cancer	bortezomib	18 Years -	National Cancer Institute (NCI)
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma	NCT00072150	Metastatic Tran... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Stage IV Urethr... Transitional Ce... Ureter Cancer	bortezomib	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium	NCT01090466	Bladder Cancer Transitional Ce... Urethral Cancer	cisplatin gemcitabine hyd... temsirolimus pharmacological...	16 Years - 120 Years	Cardiff University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: